Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape ® ). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54e68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5e10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue.
Introduction
Drug-drug interaction (DDI) is defined as a situation in which a drug modify the action or effects of another drug, lead to alter the patient's response to therapy. 1e3 It is a common problem 4, 5 and the rate of adverse drug reaction is 20e30% in routine clinical practice. 6, 7 In addition, the mortality rate related to DDI is approximately 4%. 7, 8 DDIs have various levels of severity ranging from mild to severe fatal events. 4 Drug interactions can categorized into 2 groups; potential drug drug interaction and real drug interaction. PDDI is defined as the occurrence of a potentially harmful combination. Real drug interaction can be demonstrated in clinical practice. 5, 9 Pharmacologically, drug interactions are separated into three classes: a. Pharmaceutical interactions occurs when mixing chemically incompatible drugs outside the body; b. Pharmacodynamic interactions synergistic, additive, antagonistic and sequence-dependent effects may occurs when two drug are used concomitantly; c. Pharmacokinetic interactions occurs when a drug interferes with the absorption, distribution, metabolism and/or excretion of another drug. 1, 9, 10 DDIs have three possible consequences as altered the effectiveness or increased adverse events of the drugs or unexpected response. 1, 5 The severity of fatal events related to DDIs may correlate with the polypharmacy 11, 12 in hospitalized patients. 10 Not only polypharmacy, but also disease burden, length of stay and demographic and clinical characteristics of the patient also effect this potential hazardous event.
Patients with cancer are at high risk of DDIs as chemotherapeutic drugs are used in multi-drug combination regimens. These patients also use medications for cancer-related syndromes such as pain, emesis and infection. However, an additional problem is that cancer incidence increases with aging. Also elderly patients usually have multiple comorbidities and receive multiple drugs to treat these comorbidities. 1, 12, 13 Unfortunately, the patients receiving medical treatment for cancer is at high risk for potential drug interactions. This polypharmacy increases the risk DDIs in oncology practice. In our study, we aimed to assess the frequency and severity of pDDI in hospitalized cancer patients.
Methods
Data collection were started after Trakya University Ethics Committee approved the study.
Patients
This retrospective study was conducted between January and April 2017 in our medical oncology service. A total of 327 patients who were hospitalized more than 24 h were analyzed. Patients who received drugs in a clinical trial programme were excluded.
Study design
Drugs were categorized into two groups as chemotherapy and other drugs (drugs used for supportive treatment and drugs used in treatment of comorbidities). When a drug formulation included two or more active pharmaceutical ingredients like piperacillin/ tazobactam each drug was counted separately in the analysis. However, when a patient who receiving the same medication in more than one formulation (e.g. intravenous and oral tramadol) was counted only once. Drug interactions were identified by using the checker programme (reference.medscape.com/drug-interactionchecker). PDDI was classified into three categories according to a level of severity as minor, moderate and major. "Minor" DDIs were defined as drug combinations likely to have no significant clinical relevance; "moderate" as drug combinations where a drug may modify the effect of the another drug and need to be monitored closely; "major" as drug combinations that should be usually avoided or may potentially lead to serious clinical consequences.
Statistical analysis
Descriptive statistics (mean, median) were applied to characterize all study sample with regard to demographics, cancer type, treatment objective, type of anticancer agents, comorbidities, number of drugs per patient and interaction characteristics. The difference between the groups was compared using Chi-square or Fisher's Exact tests. All data were analyzed using the Statistical Package for the Social (SPSS) version 16.0 (SPSS Inc. Chicago, IL) computer programme and a value of p < 0.05 was considered statistically significant. Table 1 showed the demographic and clinical characteristics of the patients. The median age was 61 years (interquartile range 54e68) and female to male ratio was 211/116. The most common underlying diseases were gastrointestinal cancer (30.9%), followed by lung (25.0%) and genitourinary (13.5%) cancer. Two hundredthree (80.4%) patients had metastasis and 39.1% of these (n ¼ 128) had at least one comorbid disease. The majority of patients had hypertension (73.4%), diabetes mellitus (25.7%). In addition, the median length of hospital stay of patients was 5 days (interquartile range 2e10) and fifty patients (15.3%) died during hospitalization. Ninety-eight patients received chemotherapy during admission. Approximately three quarters (76.2%) of the patients were hospitalized for palliative care. Thirty-four patients (10.4%) did not take any medication for the treatment of their primary disease.
Results

General characteristics
Drug-drug interactions
PDDI was detected in 233 patients (71.3%) who had at least one interaction, while 94 patients did not show any interaction. The median number of drugs per patient was 8 (interquartile range 5e10). The maximum number of drug used during the admission was 22. Table 2 showed that a total of 1102 potential drug-drug interactions were detected among the patients who received 2 or more medications. Only 21 (1.9%) of these were with chemotherapy drugs. Most of the interactions (n ¼ 1081, 98.1%) were together with supportive care medications. Major and moderate pDDIs were detected as 16.7% and 61.9%, respectively. Table 3 demonstrated the common pDDIs in patients who received the multiple medications. The most frequent agents included at pDDIs were opioids, SSRIs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAID), low molecular weight heparins (LWMH) and proton pump inhibitors. Opioids with opioids, SSRIs with opioids, LMWH with piperacillin, LMWHs with corticosteroids, NSAIDs with LMWHs, corticosteroids with opioids andproton pump inhibitors were common combinations. Of these, the most common interaction were opioids and opioids (n ¼ 77). Table 4 showed the pDDIs together with chemotherapy drugs. It was shown that increased length of stay were significantly associated with pDDIs (p < 0.05). The relationship between drug interaction frequency and age was not statistically significant. The result of analysis of risk factor was shown in Table 5 .
Discussion
Cancer is generally an advanced age disease. The incidence of chronic diseases and polypharmacy rates are also increasing with aging. 11, 14 It is known that an increase in the number of medications leads adverse events and drug interactions in cancer patients who were treated with multiple medications including chemotherapy and supportive care medications such as various hormonal treatments, antiemetics, analgesics. 5, 13 Additionally, hospitalized patients have a greater risk than outpatients. 15, 16 In this retrospective study, at least one drug interaction was found in 71.3% of hospitalized patients. Moreover, 16.7% of these interactions were majorlevel interactions that may require follow-up in terms of adverse effects. In a study with cancer patients, Leeuwen et al. 17 found drug interactions in 58% of the patients and 33.9% of these interactions were major. Riechelmann et al. 12 in a retrospective study found that 63% of cancer patients have drug interactions which was similar to our study. And 32% of these interactions were major. Although the rate of drug interaction were higher than the data in the literature, major serious interaction rate was lower.
Patients with cancer are at high risk for pDDIs as they use many drugs simultaneously. 10, 18 The average of medicine per capita was 8 in our study group. We revealed that the length of stay was more than 5 days which was significantly associated with potential drug interactions. The length of stay of 157 patients in the study group was more than 5 days. Similarly, Riechelmann et al. 12 defined that the length of stay was associated with potential drug interactions that were greater than 6 days. We suggest that less hospital stay leads to decreased potential drug-drug interactions.
Pain is a common symptom in cancer patients. Prevalence and severity are related to many factors such as the stage, location and metastatic site of the disease. Opioids are frequently used in clinical practice in cancer-related pain. 19, 20 Opioid analgesics may be interact with many drugs. The effectiveness and adverse events of opioids may increase with pharmacodynamic synergism, via inhibition of serotonin and/or norepinephrine reuptake. 18 The most common potential drug interactions were simultaneous use of different opioids together. There is no simultaneous use of different opioids in the symptomatic treatment of cancer-related pain in World Health Organization (WHO) and European Society for Medical Oncology (ESMO)'s guidelines. 21, 22 If we inform healthcare professionals about the correct use of opioids, we can prevent 41.8% of major pDDIs.
Venous thromboembolism occurs commonly in cancer patients and usually treated with low molecular weight heparins (LMWHs) such as enoxaparin. 23, 24 In our study, we found that LMWHs were often prescribed with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and piperacillin. On the other hand, NSAIDs are one of the most frequently used drug for pain palliation in cancer patients. 17 Simultaneous use of the NSAID and corticosteroid with LMWH have increased the risk of gastrointestinal bleeding and perforation. 25e27 We showed that 92 of the pDDIs was together with LMWHs that could increase the risk of bleeding on account of NSAID, corticosteroid, and piperacillin use. According to Table 3 The most common pDDIs involving drugs used for palliative treatment and comorbidity.
Drug Combination n Description Severity
Opioids Another common type of interaction in cancer patients is central nervous system (CNS) interactions. CNS interactions related to SSRIs are mainly reported in patients who receiving opioid analgesics simultaneously. In case of simultaneous use of opioid agonists and SSRIs together, due to the pharmacodynamic synergism, respiratory depression and sedation could be seen. 7, 18, 28 Therefore, clinical follow-up is important in the way of CNS toxicity of patients receiving this combination commonly used in oncology practice.
There are some limitations. First, retrospective clinical data of from medical records has disadvantages to control for all potential confounding bias that may influence the pDDIs. Second, data about toxicity profile may have missing data due to incomplete identification of adverse events considering the limitation of the retrospective study. Another major limitation was the difficulty in measuring the number of potential interactions that result in clinically adverse effects on the other hand, clinical results of drug interactions in the study were not investigated, but rather on their potential for occurrence. Nevertheless, most interaction control programmes do not consider for the treatment dosage, duration, and individual changes in the patients. Finally, one of our major limitation was to use only one interaction checker programme.
Although the best method to prevent pDDIs is not completely known, it is necessary to be aware of this issue and be particularly careful in groups of patients with increased risk for drug interactions. It is not known whether physicians are well informed about these pDDIs and whether they take precautions to prevent complications. A multidisciplinary approach can be proposed where physicians, pharmacists, nurses are involved in optimizing treatment and preventing interactions. Though, a computer-based scanning method may be a useful tool to interactions.
In conclusion, the incidence of pDDIs are high in especially hospitalized cancer patients and many of them are clinically important. Long-term hospitalized patients are under risk of pDDIs. Screening and identification of drug interactions may prevent the adverse drug events in cancer patients.
